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ABSTRACT
Introduction Chronic respiratory diseases (CRDs) are 
common and disabling conditions that can result in social 
isolation and economic hardship for patients and their families. 
Pulmonary rehabilitation (PR) improves functional exercise 
capacity and health- related quality of life (HRQoL) but practical 
barriers to attending centre- based sessions or the need for 
infection control limits accessibility. Home- PR offers a potential 
solution that may improve access. We aim to systematically 
review the clinical effectiveness, completion rates and 
components of Home- PR for people with CRDs compared with 
Centre- PR or Usual care.
Methods and analysis We will search PubMed, CINAHL, 
Cochrane, EMBASE, PeDRO and PsycInfo from January 1990 
to date using a PICOS search strategy (Population: adults with 
CRDs; Intervention: Home- PR; Comparator: Centre- PR/Usual 
care; Outcomes: functional exercise capacity and HRQoL; 
Setting: any setting). The strategy is to search for ‘Chronic 
Respiratory Disease’ AND ‘Pulmonary Rehabilitation’ AND 
‘Home- PR’, and identify relevant randomised controlled trials 
and controlled clinical trials. Six reviewers working in pairs 
will independently screen articles for eligibility and extract 
data from those fulfilling the inclusion criteria. We will use the 
Cochrane risk- of- bias tool and Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) approach 
to rate the quality of evidence. We will perform meta- analysis 
or narrative synthesis as appropriate to answer our three 
research questions: (1) what is the effectiveness of Home- PR 
compared with Centre- PR or Usual care? (2) what components 
are used in effective Home- PR studies? and (3) what is the 
completion rate of Home- PR compared with Centre- PR?
Ethics and dissemination Research ethics approval is not 
required since the study will review only published data. The 
findings will be disseminated through publication in a peer- 
reviewed journal and presentation in conferences.
PROSPERO registration number CRD42020220137.
INTRODUCTION
Chronic respiratory diseases (CRDs) including 
chronic obstructive pulmonary disease (COPD), 
remodelled asthma, pulmonary impairment 
after tuberculosis (PIAT), interstitial lung disease 
(ILD), bronchiectasis and cystic fibrosis (CF), 
among others, affect an estimated 545 million 
people globally.1 Around 4 million people die 
prematurely from CRDs each year across the 
world,2 and COPD, asthma, and tuberculosis 
are among the top 30 conditions that cause high 
rates of disability- adjusted life- years.3 CRDs, in 
particular COPD, are associated with breath-
lessness, fatigue and muscle dysfunction which 
contribute to reduced physical activity levels 
and functional exercise capacity.4 Independent 
of the severity of airway obstruction, this func-
tional impairment is related to decreased health- 
related quality- of- life (HRQoL), increased 
adverse events and mortality.5 6
Pulmonary rehabilitation (PR) is an essen-
tial component of CRD care7 that improves 
functional exercise capacity, HRQoL and 
reduces the burden of chronic respiratory 
symptoms.8 9 It is defined as a comprehensive, 
Strengths and limitations of this study
 ► A systematic review of the effectiveness, completion 
rates and components of Home- pulmonary rehabil-
itation (Home- PR) for chronic respiratory diseases 
(CRDs) is needed to inform patients and providers 
especially when healthcare accessibility is restricted 
by geography, demography or during pandemics.
 ► The review methods are in accordance with 
Cochrane methodology and Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses 
publishing guidelines.
 ► Issues like heterogeneity, poor reporting of published 
trials may affect confidence in results although we 
expect to provide robust evidence supporting the 
successful implementation of Home- PR services for 
people with CRDs.
 ► The multi- disciplinary, multinational research team 
will enable a nuanced interpretation of the findings.
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multidisciplinary and multifaceted intervention based on 
a thorough patient assessment, followed by individually 
tailored therapies that are designed to improve the phys-
ical and psychological conditions of people with CRDs and 
to support the long- term adherence to health- enhancing 
behaviours.10 11 The components of PR include exercise 
training, education, nutritional support, smoking cessa-
tion, lifestyle modification and self- management, among 
others. PR is indicated for patients who continue to expe-
rience symptoms despite optimising pharmacological 
treatment.12 13
Despite proven effectiveness,11 14 15 PR is under- used. 
The reasons for poor attendance and completion rates are 
multifactorial and commonly identified barriers include: 
low referral rate; inconvenient timing of the programmes 
necessitating time off work; geographical distance to PR 
centres which can be made worse in some countries by 
poor transport infrastructure.16–20 While pertinent even 
in high- income countries21–23 many of these barriers are 
exacerbated in low/middle- income countries (LMICs) 
where there is a lack of structured PR facilities especially 
in rural communities.24 25
Typically, PR is provided in hospital centres 
(Centre- PR),26 but globally different models are tailored 
to the local context such as Community- PR,27 and 
Home- PR with telephone- mentoring,28 or telerehabilita-
tion programmes.29 The ongoing COVID- 19 pandemic 
has added strain to PR services by increasing the popu-
lation for whom PR is indicated and adding barriers to 
the delivery of the treatment due to cross- infection issues. 
There is, therefore, an increased interest in Home- PR30 as 
a strategy to overcome these barriers. A Cochrane review 
of 65 studies (3822 patients) has established the effec-
tiveness of standard Centre- PR programmes in COPD14 
with a subgroup analysis suggesting that PR delivered in a 
hospital centre may have a greater treatment effect than 
PR delivered in the community/home. Using the same 
definitions, three reviews (Wuytack et al,31 Chen and Xiao- 
XiaoYang32 and Neves et al33) included studies comparing 
PR delivered in different settings and both concluded that 
Home/Community- PR could be as effective as Centre- PR 
for people with COPD. Combining home and commu-
nity services, however, overlooks the distinction between a 
community- based group supervised in person by a health-
care professional and a programme delivered to an indi-
vidual in their own home. These reviews are also limited 
by disease (COPD only), although there is evidence that 
PR is of benefit in bronchiectasis11 and ILD.34 Taito et al 
in a scoping review also included people recovering from 
COVID- 19.35
A recently published Cochrane review assessed the 
effectiveness and safety of telerehabilitation for people 
with CRDs when compared with Centre- PR or no reha-
bilitation36 and concluded that primary or mainte-
nance PR telerehabilitation achieved similar outcomes 
to Centre- PR. In this review, remote delivery of PR was 
defined by the use of telecommunications technology 
to deliver PR services to individuals or groups (either 
physical or virtual) in any location, including in the 
patient’s home or at a healthcare centre. In contrast, in 
our review, the definition of Home- PR is that the sessions 
are undertaken by an individual by themselves (though a 
family member may be involved) and typically at home. 
Apart from baseline and post- PR assessments,35 the 
patient does not attend a centre (either a hospital centre 
or a local ‘satellite’ centre) and is not supervised face- to- 
face by a healthcare professional (though there may be 
remote communication from a healthcare professional 
for some or all of the session).
An additional distinction is that we defined Home- PR 
as comprising both exercise and at least one non- exercise 
component for a duration of not less than 4 weeks. This 
contrasts with other reviews32 36 37 that included exer-
cise training programmes (ie, without the non- exercise 
component that is normally included in Centre- PR8). 
These reviews did not seek to identify components with 
greater impact on positive patient outcomes. We there-
fore aim to systematically review the literature to assess 
the effectiveness, completion rates and components used 
in effective Home- PR for people with CRDs.
OBJECTIVES
In people with CRDs, we will:
1. Assess the clinical effectiveness of Home- PR (see ta-
ble 1 for definition) compared with Centre- PR or 
Usual care at improving health outcomes (ie, exercise 
capacity (primary outcome), HRQoL (primary out-
come), dyspnoea, muscle fatigue, exacerbations and 
hospitalisations for CRD).
2. Describe the components of Home- PR that are associ-
ated with successful interventions (eg, intensity of ex-
ercise, duration of the programme, education and/or 
other non- exercise components, frequency of super-
vision, information/resources, involvement of family 
members).
3. Compare the completion rate (defined as participat-
ing in at least 70% of PR sessions) of Home- PR with 
Centre- PR.
METHODS AND ANALYSIS
We will follow Cochrane methodology,37 and use Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses 
(PRISMA) guidelines38 to report our review findings. The 
review is registered with PROSPERO, any changes to the 
published record will be reported.
Search strategy
We will develop a search strategy, including disease- 
specific search terms, and identify records through 
searching the following databases: PubMed, CINAHL, 
Cochrane, EMBASE, PeDRO and PsycInfo (online 
supplemental appendix 1). The strategy will search for 
‘Chronic Respiratory Disease’ AND ‘Pulmonary Rehabil-
itation’ AND ‘Home- PR’ from 1990, when global COPD 
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guidelines first recommended PR.39 We will check refer-
ence lists and conduct forward citation on included 
studies and on Cochrane reviews of PR.14 17 We will 
not impose any language restriction, and will arrange 
for translation to English to enable selection and data 
extraction.
Selection process
We will select studies that compare Home- PR for people 
with CRDs with Centre- PR and/or Usual care (see defi-
nitions and details of our PICOS (Population, Interven-
tion, Comparison, Outcomes, Setting) criteria in table 1). 
Following training on 100 randomly selected records, six 
reviewers working in pairs (MNU and TJ, JPE and FTM, 
DA and PJ) will duplicate screen titles and abstracts 
and identify potentially eligible studies. Disagreements 
will be resolved by discussion with the review team (HP, 
RAR, SML, GMMH, NSH and SCC) as necessary. After 
retrieval of the full text of potentially eligible studies, the 
six reviewers working in the same pairs will independently 
screen the studies against the selection criteria. Disagree-
ments will be resolved by discussion within the team to 
arbitrate and determine rules for operationalising the 
inclusion/exclusion criteria. Anything that remains 
unclear, will be clarified by contacting the authors; if 
this fails, the study will be listed as ‘potentially relevant 
study’. All processes will be reported in a PRISMA flow 
diagram,38 and excluded full- text papers will be tabulated 
with reasons for exclusion.
Outcome measurement
Our primary outcomes will be HRQoL and functional 
exercise capacity. We are interested in preassessment and 
postassessment or if an immediate post is not provided, 
the nearest figure to that. See table 1 for details and 
description of secondary outcomes.
Data management and extraction
We will develop a customised data extraction form based 
on Cochrane Effective Practice and Organisation of Care 
(EPOC) guidance.40 This form will be piloted by all the 
researchers to standardised use and revised to endure 
that it captures all relevant information including the 
PICOS criteria, definitions used and outcome measure-
ments. Data extraction will be carried out by six reviewers 
working in pairs (MNU, TJ, JPE, FTM, DA, PJ). General 
information such as date of extraction, name of the 
reviewer, article title, trial eligibility including type of 
study, participants, methods, number of participants 
in each group, reference of trials, intervention group, 
cointerventions, serious adverse events, description of 
funding, ethical approval will be extracted from included 
full- text papers. We will contact authors for any missing 
data. If this is not possible and the missing data seem to 
introduce serious bias, we will perform sensitivity anal-
ysis of the impact of including such studies in the overall 
assessment of results.
Risk of bias assessment
Methodological quality of all included randomised 
controlled trials (RCTs) will be assessed independently by 
reviewers (MNU,TJ, JPE, FTM, DA, PJ working in pairs) 
using the ‘Cochrane Risk of Bias’ tool.37 Discrepancies 
will be resolved by discussion with the team. We will assess 
the papers for selection, performance, detection, attri-
tion, reporting and other sources of bias, and assess the 
overall risk of bias. We will record and tabulate a summary 
of the assessment with the overall judgement. To assess 
the risk of bias of clinical controlled trials, we will use the 
‘Risk of Bias in Non- randomised Studies of Interventions’ 
tool.41 We will include all studies in our primary analysis 
but take into account the risk of bias of the studies when 
considering the intervention effects. If there are suffi-
cient studies we may undertake sensitivity analyses omit-
ting studies at high risk of bias.
Heterogeneity and reporting bias
We will assess and investigate reasons for any heteroge-
neity using the I² statistic42 and create a funnel plot to test 
for publication bias43 unless we have fewer than 10 trials.
Data analysis
Objective 1
We plan to undertake meta- analysis for the primary 
outcomes and some secondary outcomes (eg, HRQoL, 
dyspnoea, muscle fatigue, exacerbations, hospitalisa-
tions), comparing Home- PR first with Usual care and 
then with Centre- PR. Heterogeneous outcomes for which 
a meta- analysis is inappropriate will be synthesised narra-
tively. For homogenous data from RCTs, we will perform 
a pooled quantitative synthesis using an inverse variance 
method and a random- effects model in the meta- analysis. 
We will consider pooled mean differences if the same 
outcome measurement tool is used in the included RCTs. 
However, if (as expected) outcome measurement tool 
varies among trials, we will consider standardised mean 
differences (SMDs). Our hypothesis is that Home- PR is 
non- inferior to Centre- PR, but a clinically meaningful 
non- inferiority margin cannot be inferred using SMDs. 
If sufficient studies use the same measure for functional 
exercise capacity or health- related quality of life, we will 
define the non- inferiority margin as the minimum clini-
cally important difference. We will use Review Manager 
software (RevMan 2020, V.5.4.1) to perform meta- analysis.
Objective 2
The components of Home- PR will be described and 
a matrix compiled to identify any associations with 
successful interventions.
Objective 3
We will use a narrative approach to synthesise completion 
in Home- PR and Centre- PR groups. If sufficient studies 
report completion rates, we will consider a sub- group 
analysis based on the threshold of 70% completion.
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Subgroup analyses
Depending on the papers included, we will perform 
subgroup analyses. Subgroups may include high/
LMICs, CRD diagnosis (eg, COPD, ILD, bronchiectasis, 
stable post- COVID lung disease, mixed CRD), severity as 
defined in internationally recognised guidelines,12 inten-
sity of intervention (number of weeks, sessions per week, 
workload, completion rate) and arrangements for super-
vision of the PR programme.
Interpretation of findings
We will use the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) approach44 
to assess the quality of evidence and strength of recom-
mendations for the primary outcomes and the important 
secondary outcomes (listed in table 1).
Patient and public involvement
Patients who are involved in the RESPIRE programme of 
work on PR have endorsed the importance of Home- PR 
for improving accessibility to rehabilitation. They will be 
involved in interpreting the findings and the implications 
for intervention development and the overall programme 
of work
DISCUSSION
Home- PR has particular resonance at the time of devel-
oping this protocol because of the COVID- 19 pandemic 
which has resulted in Centre- PR services being halted. 
More generally, there is an interest in offering Home- PR 
as a strategy to overcome the practical barriers of time 
and distance and increase the accessibility of PR services 
especially in LMICs. There are, however, concerns that 
the relative lack of supervision and the loss of peer group 
support may reduce effectiveness. Hence a review on the 
effectiveness of Home- PR and its components is timely 
to inform patients, professionals and healthcare service 
providers considering Home- PR options.
ETHICS AND DISSEMINATION
This systematic review protocol will use publicly available 
data without direct involvement of human participants. 
Therefore, approval from an ethics committee is not 
essential. We will present our review findings at national 
and international scientific meetings and conferences, 
and publish in a peer- reviewed journal. In addition, we 
will use innovative dissemination strategies including 
virtual seminars and social media.
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